Summary of studies examining impact of surveillance on OAC outcomes
| Study | Year | Total patients with OAC and GOJAC | No of patients with cancer detected during surveillance | Association with earlier cancer stage | Association with improved survival | Grade of evidence |
|---|---|---|---|---|---|---|
| Streitz et al73 | 1993 | 77 | 11 | p=0.006 | p=0.007 | III |
| Peters et al74 | 1994 | 52 | 17 | p=0.01 | p=0.05 | III |
| Van Sandick et al75 | 1998 | 70 | 16 | p=0.0001 | p=0.0029 | III |
| Corley et al76 | 2002 | 23 | 15 | p=0.02 | p=0.001 | III |
| Cooper et al77 | 2002 | 1633 | 9.70% | p<0.001* | p<0.01 | III |
| Fountoulakis et al78 | 2004 | 91 | 17 | p=0.001 | p=0.008 | III |
| Rubenstain et al79 | 2008 | 155 | 25 | p=0.02 | HR 0.82 (95% CI 0.52 to 1.29) | III |
| Cooper et al137 | 2009 | 2754 | 8.10% | p=0.001 | p=0.001 | III |
*0.06 for cardia cancer.
GOJAC, gastro-oesophageal junction adenocarcinoma; HR, hazard ratio; OAC, oesophageal adenocarcinoma.